ResMed Ready To Supply The Digital Answers To Health Care’s Demand Challenges
Repiratory and sleep group ResMed says COVID-19 has accelerated the transformation of care delivery
Executive Summary
ResMed’s respiratory device portfolio has put the company front and center of the global medtech industry’s efforts to bring COVID-19 under control. UK and Ireland country manager Antoine Valterio tells Medtech Insight how the company rose to the challenge, and how providers are now seeing digital technologies in a new light.
You may also be interested in...
Exec Chat: ResMed's CEO Mick Farrell Outlines 2025 Strategy For 250 Million Users
ResMed's CEO Mick Farrell outlined the company's 2025 strategy: double-digit growth, drive up its user base to 250 million people and becoming the leading digital health company in both sleep apnea and chronic obstructive pulmonary (COPD) disease. Medtech Insight sat down with Farrell at ResMed's San Diego headquarters to learn more.
ResMed Continues To Build Digital-Medicine Business With $225M Acquisition Of Propeller Health
Propeller Health bills itself as a digital respiratory therapeutics company, providing a mobile platform that communicates with sensors on patients' inhaler devices to help them manage chronic obstructive pulmonary disease and asthma. This the second major acquisition ResMed has announced in the last month.
The Sustainability Stakes Are Rising: ‘We Cannot Recycle Our Way Out Of This’
The journey to Net Zero, described as ‘the defining issue of our time,’ will get harder in the coming decade. Failure to keep up the pressure will result in more long-term health conditions, increasing deaths and higher costs. The UK NHS is a Net Zero exemplar globally, but without a systemic approach, its compliance efforts could stutter.